Shigella conjugate vaccine efficacy trial in controlled human model and potential immune correlates of protection

Shigella conjugate vaccine efficacy trial in controlled human model and potential immune correlates of protection

Bibliographic Details
Main Authors:	Rubhana Raqib, Malabi Venkatesan
Format:	Article
Language:	English
Published:	Elsevier 2021-04-01
Series:	EBioMedicine
Online Access:	http://www.sciencedirect.com/science/article/pii/S2352396421001365

Similar Items

A phase I trial of WRSS1, a Shigella sonnei live oral vaccine in Bangladeshi adults and children
by: Rubhana Raqib, et al.
Published: (2019-06-01)

Human challenge study with a Shigella bioconjugate vaccine: Analyses of clinical efficacy and correlate of protection
by: Kawsar R. Talaat, et al.
Published: (2021-04-01)

B memory cell responses to LPS, IVP and IpaB antigen after oral vaccination with Shigella sonnei vaccine candidates WRSs2 and WRSs3
by: Malabi M. Venkatesan, et al.
Published: (2024-01-01)

B memory cell responses to LPS, IVP and IpaB antigen after oral vaccination with Shigella sonnei vaccine candidates WRSs2 and WRSs3.
by: Malabi M Venkatesan, et al.
Published: (2024-01-01)

Antibody in Lymphocyte Supernatant (ALS) responses after oral vaccination with live Shigella sonnei vaccine candidates WRSs2 and WRSs3 and correlation with serum antibodies, ASCs, fecal IgA and shedding
by: Malabi M. Venkatesan, et al.
Published: (2021-01-01)

Antibody in Lymphocyte Supernatant (ALS) responses after oral vaccination with live Shigella sonnei vaccine candidates WRSs2 and WRSs3 and correlation with serum antibodies, ASCs, fecal IgA and shedding.
by: Malabi M Venkatesan, et al.
Published: (2021-01-01)

A Novel Shigella O-Polysaccharide–IpaB Conjugate Vaccine Elicits Robust Antibody Responses and Confers Protection against Multiple Shigella Serotypes
by: Girmay Desalegn, et al.
Published: (2023-06-01)

Phenylbutyrate counteracts Shigella mediated downregulation of cathelicidin in rabbit lung and intestinal epithelia: a potential therapeutic strategy.
by: Protim Sarker, et al.
Published: (2011-01-01)

Pivotal <i>Shigella</i> Vaccine Efficacy Trials—Study Design Considerations from a <i>Shigella</i> Vaccine Trial Design Working Group
by: Patricia B. Pavlinac, et al.
Published: (2022-03-01)

A trial of a typhoid conjugate vaccine in children in Malawi
by: Priya Venkatesan
Published: (2021-12-01)

Classical and novel strategies to develop a Shigella glycoconjugate vaccine: from concept to efficacy in human
by: Louis-Antoine Barel, et al.
Published: (2019-06-01)

Immunization of Rabbits with a Quadrivalent Shigella Bioconjugate Vaccine Induces Functional Antibodies Reactive with Shigella Isolates from Kenya
by: Elizabeth A. Odundo, et al.
Published: (2022-06-01)

Assessing correlates of protection in vaccine trials: statistical solutions in the context of high vaccine efficacy
by: Andrea Callegaro, et al.
Published: (2019-03-01)

The identification of novel immunogenic antigens as potential Shigella vaccine components
by: de Alwis, R, et al.
Published: (2021)

The identification of novel immunogenic antigens as potential Shigella vaccine components
by: Ruklanthi de Alwis, et al.
Published: (2021-01-01)

Functional antibodies as immunological endpoints to evaluate protective immunity against Shigella
by: Esther Ndungo, et al.
Published: (2020-01-01)

Pneumococcal conjugate vaccine induced IgG and nasopharyngeal carriage of pneumococci: Hyporesponsiveness and immune correlates of protection for carriage
by: Ojal, J, et al.
Published: (2017)

An Experimental Adult Zebrafish Model for Shigella Pathogenesis, Transmission, and Vaccine Efficacy Studies
by: Debaki R. Howlader, et al.
Published: (2022-06-01)

Potential SARS-CoV-2 Immune Correlates of Protection in Infection and Vaccine Immunization
by: Yongjun Sui, et al.
Published: (2021-01-01)

Applying mathematical tools to accelerate vaccine development: modeling Shigella immune dynamics.
by: Courtney L Davis, et al.
Published: (2013-01-01)

A clinically parameterized mathematical model of Shigella immunity to inform vaccine design.
by: Courtney L Davis, et al.
Published: (2018-01-01)

The <i>Shigella</i> Vaccines Pipeline
by: Calman Alexander MacLennan, et al.
Published: (2022-08-01)

Efficacy and potential of phage therapy against multidrug resistant Shigella spp.
by: Tang, Swee Seong, et al.
Published: (2019)

Efficacy and potential of phage therapy against multidrug resistant Shigella spp.
by: Swee-Seong Tang, et al.
Published: (2019-04-01)

<i>Shigella</i> -Specific Immune Profiles Induced after Parenteral Immunization or Oral Challenge with Either Shigella flexneri 2a or Shigella sonnei
by: Kristen A. Clarkson, et al.
Published: (2021-08-01)

Immune response characterization in a human challenge study with a Shigella flexneri 2a bioconjugate vaccine
by: Kristen A. Clarkson, et al.
Published: (2021-04-01)

Changing emergence of Shigella sero-groups in Bangladesh: observation from four different diarrheal disease hospitals.
by: Sumon Kumar Das, et al.
Published: (2013-01-01)

Shigella virulence protein VirG is a broadly protective antigen and vaccine candidate
by: Girmay Desalegn, et al.
Published: (2024-01-01)

Cross-Protective Shigella Whole-Cell Vaccine With a Truncated O-Polysaccharide Chain
by: Min Jung Kim, et al.
Published: (2018-10-01)

Correction: A clinically parameterized mathematical model of Shigella immunity to inform vaccine design.
by: Courtney L Davis, et al.
Published: (2018-01-01)

Immune correlates analysis of the PREVENT-19 COVID-19 vaccine efficacy clinical trial
by: Youyi Fong, et al.
Published: (2023-01-01)

Long-term protection after immunization with protein-polysaccharide conjugate vaccines in infancy.
by: Blanchard-Rohner, G, et al.
Published: (2011)

Potential Protectivity of a Conjugated COVID-19 Vaccine against Tetanus
by: Delaram Doroud, et al.
Published: (2024-02-01)

T cell mediated immunity induced by the live-attenuated Shigella flexneri 2a vaccine candidate CVD 1208S in humans
by: Franklin R. Toapanta, et al.
Published: (2018-03-01)

Frontiers in <i>Shigella</i> Vaccine Development
by: Calman Alexander MacLennan, et al.
Published: (2022-09-01)

Immune Response Characterization after Controlled Infection with Lyophilized <named-content content-type="genus-species">Shigella sonnei</named-content> 53G
by: Kristen A. Clarkson, et al.
Published: (2020-10-01)

Phase 3 efficacy analysis of a typhoid conjugate vaccine trial in Nepal
by: Shakya, M, et al.
Published: (2019)

Phase 3 efficacy analysis of a typhoid conjugate vaccine trial in Nepal
by: Shakya, M, et al.
Published: (2019)

Immune Correlates of Protection from Filovirus Efficacy Studies in Non-Human Primates
by: Cheryl A. Triplett, et al.
Published: (2022-08-01)

In vitro adhesion and invasion inhibition of <it>Shigella dysenteriae</it>, <it>Shigella flexneri </it>and <it>Shigella sonnei </it>clinical strains by human milk proteins
by: Giugliano Loreny, et al.
Published: (2004-04-01)